Fintel reports that on December 23, 2024, D. Boral Capital initiated coverage of Omeros (NasdaqGM:OMER) with a Buy recommendation.
Analyst Price Forecast Suggests 333.83% Upside
As of December 23, 2024, the average one-year price target for Omeros is $43.86/share. The forecasts range from a low of $43.43 to a high of $45.15. The average price target represents an increase of 333.83% from its latest reported closing price of $10.11 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Omeros is 49MM. The projected annual non-GAAP EPS is -1.77.
What is the Fund Sentiment?
There are 215 funds or institutions reporting positions in Omeros. This is an increase of 12 owner(s) or 5.91% in the last quarter. Average portfolio weight of all funds dedicated to OMER is 0.01%, an increase of 0.50%. Total shares owned by institutions increased in the last three months by 9.70% to 28,276K shares. 
The put/call ratio of OMER is 0.50, indicating a bullish outlook.
What are Other Shareholders Doing?
Ingalls & Snyder holds 4,539K shares representing 7.83% ownership of the company. In its prior filing, the firm reported owning 4,593K shares , representing a decrease of 1.18%. The firm decreased its portfolio allocation in OMER by 12.28% over the last quarter.
Stifel Financial holds 1,904K shares representing 3.29% ownership of the company. In its prior filing, the firm reported owning 1,903K shares , representing an increase of 0.08%. The firm decreased its portfolio allocation in OMER by 78.42% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,880K shares representing 3.24% ownership of the company. No change in the last quarter.
D. E. Shaw holds 1,605K shares representing 2.77% ownership of the company. In its prior filing, the firm reported owning 1,576K shares , representing an increase of 1.80%. The firm decreased its portfolio allocation in OMER by 8.60% over the last quarter.
IWM - iShares Russell 2000 ETF holds 1,473K shares representing 2.54% ownership of the company. In its prior filing, the firm reported owning 1,383K shares , representing an increase of 6.12%. The firm decreased its portfolio allocation in OMER by 10.14% over the last quarter.
Omeros Background Information
(This description is provided by the company.)
Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
